Repare Therapeutics Inc. (RPTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RPTX currently has 43M outstanding shares. with significant dilution risk as 112M authorized shares could dilute existing holders by 261.1%. The company has minimally diluted shareholders by 1.82% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 14, 2025 |
10-Q filing | 43.0M shares outstanding |
43M | 110M |
| Aug 08, 2025 |
10-Q filing | 42.9M shares outstanding |
43M | 110M |
| May 13, 2025 |
10-Q filing | 42.6M shares outstanding |
43M | 110M |
| Mar 03, 2025 |
10-K filing | 42.4M shares outstanding |
42M | 110M |
| Nov 07, 2024 |
10-Q filing | 42.5M shares outstanding |
42M | 110M |
| Aug 06, 2024 |
10-Q filing | 42.4M shares outstanding |
42M | 110M |
| Aug 06, 2024 |
S-3 filing: The company may offer common shares, preferred shares and/or debt securities for a total aggregate amount not to exceed $350,000,000. |
42M | 110M |
| May 07, 2024 |
10-Q filing | 42.2M shares outstanding |
42M | 0 |
| Feb 28, 2024 |
10-K filing | 42.1M shares outstanding |
42M | 0 |
| Nov 09, 2023 |
10-Q filing | 42.1M shares outstanding |
42M | 0 |
| Aug 09, 2023 |
10-Q filing | 42.1M shares outstanding |
42M | 0 |
| May 09, 2023 |
10-Q filing | 42.0M shares outstanding |
42M | 0 |
| Feb 28, 2023 |
10-K filing | 41.9M shares outstanding |
42M | 0 |
| Nov 09, 2022 |
10-Q filing | 41.9M shares outstanding |
42M | 0 |
| Aug 04, 2022 |
10-Q filing | 41.9M shares outstanding |
42M | 0 |
| May 05, 2022 |
10-Q filing | 41.9M shares outstanding |
42M | 0 |
| Mar 02, 2022 |
POS AM filing: The filing is a POS AM (Post-Effective Amendment) that registers a combination offering of common shares, preferred shares, and debt securities, with an aggregate initial offering price not exceeding $350,000,000. |
42M | 0 |
| Mar 01, 2022 |
10-K filing | 41.9M shares outstanding |
42M | 0 |
| Nov 10, 2021 |
10-Q filing | 41.7M shares outstanding |
42M | 0 |
| Aug 12, 2021 |
10-Q filing | 37.1M shares outstanding |
37M | 0 |
| May 13, 2021 |
10-Q filing | 37.0M shares outstanding |
37M | 0 |
| Mar 04, 2021 |
10-K filing | 36.9M shares outstanding |
37M | 0 |
| Nov 12, 2020 |
10-Q filing | 36.8M shares outstanding |
37M | 0 |
| Aug 13, 2020 |
10-Q filing | 36.8M shares outstanding |
37M | 0 |
| Jun 17, 2020 |
S-1/A filing: This S-1/A filing describes a proposed initial public offering of common stock. The number of common shares to be outstanding after this offering is based on 24,057,559 common shares outstanding as of March 31, 2020, which gives effect to (i) the conversion of all outstanding preferred shares into an aggregate of 21,558,393 common shares and (ii) the automatic exercise of the warrant held by an affiliate of Bristol Myers Squibb into an aggregate of 789,474 common shares, based on an assumed initial public offering price of $19.00 per share |
24M | 0 |